Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Financial Performance - Zai Lab Limited reported revenue of $106.49 million for the quarter ended March 2025, reflecting a year-over-year increase of 22.2$0.45, an improvement from -$0.55 in the same quarter last year [1] - The reported revenue was below the Zacks Consensus Estimate of$117.09 million by 9.06% [1] - The EPS exceeded the consensus estimate of -$0.50 by 10.00$49.53 million, surpassing the average estimate of $48.32 million from three analysts [4] - Product revenue for OPTUNE reached$11.36 million, exceeding the average estimate of $8.35 million [4] - Product revenue for VYVGART was$18.11 million, falling short of the average estimate of $31.75 million [4] - Product revenue for NUZYRA was$15.12 million, slightly above the average estimate of $14.39 million [4] - Product revenue for QINLOCK was$8.51 million, exceeding the average estimate of $8.21 million [4] Stock Performance - Shares of Zai Lab Limited have returned +4.8% over the past month, compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]